Global Anti-tuberculosis APIs Market Growth 2025-2031

The global Anti-tuberculosis APIs market size is predicted to grow from US$ 291 million in 2025 to US$ 525 million in 2031; it is expected to grow at a CAGR of 10.4% from 2025 to 2031.

Anti-tuberculosis APIs are active pharmaceutical ingredients (APIs) used in the treatment of tuberculosis (TB), an infectious disease caused by Mycobacterium tuberculosis. These APIs are classified into first-line and second-line drugs, depending on their effectiveness and resistance profile.

United States market for Anti-tuberculosis APIs is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Anti-tuberculosis APIs is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Anti-tuberculosis APIs is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Anti-tuberculosis APIs players cover Calyx Chemicals and Pharmaceuticals Ltd., Linaria Chemicals (Thailand) Ltd, Minakem, Lupin Limited, Anuh Pharma Ltd., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LP Information, Inc. (LPI) ' newest research report, the “Anti-tuberculosis APIs Industry Forecast” looks at past sales and reviews total world Anti-tuberculosis APIs sales in 2024, providing a comprehensive analysis by region and market sector of projected Anti-tuberculosis APIs sales for 2025 through 2031. With Anti-tuberculosis APIs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anti-tuberculosis APIs industry.

This Insight Report provides a comprehensive analysis of the global Anti-tuberculosis APIs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Anti-tuberculosis APIs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Anti-tuberculosis APIs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anti-tuberculosis APIs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anti-tuberculosis APIs.

This report presents a comprehensive overview, market shares, and growth opportunities of Anti-tuberculosis APIs market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Pyrazinamide APIs
Isoniazid APIs
Rifampicin APIs
Ethambutol HCL APIs
Other

Segmentation by Application:
Tablets
Capsules
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Calyx Chemicals and Pharmaceuticals Ltd.
Linaria Chemicals (Thailand) Ltd
Minakem
Lupin Limited
Anuh Pharma Ltd.
Macleods Pharmaceuticals Ltd.
Amsal Chem Private Limited
Taizhou Tianrui Pharmaceutical Co.,Ltd.
Zhejiang Haizhou Pharmaceutical Co., Ltd.
Chongqing Huapont Pharmaceutical Co., Ltd.
Tonglian Group
Guangan Bingde Pharmaceutical Co., LTD.
Hebei Xingang Pharmaceutical Co., Ltd.
Luohe Chief Pharmaceutical Co, Ltd.
Zhengzhou Minzhong Pharmaceutical Co., Ltd.
China Res Double-Crane Pharmaceutical
Tianjin Handewei Pharmaceutical Co.,Ltd
YUKI GOSEI KOGYO CO.,LTD
Shanghai New Asia Pharmaceutical Co. Ltd.
Suzhou Fifth Pharmaceutical Factory Co.
Maneesh Pharmaceuticals Ltd.
Wuhan Wuyao Pharmaceutical Co., Ltd.
Cadila Pharmaceuticals
Guangzhou Baiyunshan Mingxing Pharmaceutical Co.,Ltd.
PKU HealthCare Corp., Ltd.
Northeast Pharmaceutical Group Co., Ltd.
Godavari Drugs Limited
Camus Pharma

Key Questions Addressed in this Report

What is the 10-year outlook for the global Anti-tuberculosis APIs market?

What factors are driving Anti-tuberculosis APIs market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Anti-tuberculosis APIs market opportunities vary by end market size?

How does Anti-tuberculosis APIs break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.